My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 182

    1.

    Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.

    Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Kawakubo M, Buchanan TA.

    Diabetes. 2006 Feb;55(2):517-22.PMID: 16443789 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

    Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP.

    Diabetes. 2002 Sep;51(9):2796-803.PMID: 12196473 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.

    Xiang AH, Hodis HN, Kawakubo M, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Liu CR, Liu CH, Buchanan TA.

    Atherosclerosis. 2008 Jul;199(1):207-14. Epub 2007 Dec 4.PMID: 18054942 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.

    Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, Xiang A, Azen S, Buchanan TA.

    Diabetes. 1996 Nov;45(11):1572-9.PMID: 8866563 [PubMed - indexed for MEDLINE]Related articles

    5.

    Coordinate changes in plasma glucose and pancreatic beta-cell function in Latino women at high risk for type 2 diabetes.

    Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA.

    Diabetes. 2006 Apr;55(4):1074-9.PMID: 16567531 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.

    Xiang AH, Peters RK, Kjos SL, Goico J, Ochoa C, Marroquin A, Tan S, Hodis HN, Azen SP, Buchanan TA.

    J Clin Endocrinol Metab. 2004 Jun;89(6):2846-51.PMID: 15181067 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.

    Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A, Goico J, Ochoa C, Azen SP.

    Diabetes. 2000 May;49(5):782-8.PMID: 10905487 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes.

    Rasouli N, Kern PA, Reece EA, Elbein SC.

    Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E359-65. Epub 2006 Sep 12.PMID: 16968813 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.

    Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA; Troglitazone in Prevention of Diabetes (TRIPOD) study.

    Diabetes Care. 2004 Jun;27(6):1365-8.PMID: 15161789 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.

    Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T.

    Metabolism. 2006 Jan;55(1):20-5.PMID: 16324915 [PubMed - indexed for MEDLINE]Related articles

    11.

    TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

    Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA.

    Control Clin Trials. 1998 Apr;19(2):217-31.PMID: 9551285 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

    Sourij H, Zweiker R, Wascher TC.

    Diabetes Care. 2006 May;29(5):1039-45.PMID: 16644634 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    14.

    Value of the intravenous and oral glucose tolerance tests for detecting subtle impairments in insulin sensitivity and beta-cell function in former gestational diabetes.

    Tura A, Mari A, Prikoszovich T, Pacini G, Kautzky-Willer A.

    Clin Endocrinol (Oxf). 2008 Aug;69(2):237-43. Epub 2008 Jan 10.PMID: 18194489 [PubMed - indexed for MEDLINE]Related articles

    15.

    Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus.

    Peters RK, Kjos SL, Xiang A, Buchanan TA.

    Lancet. 1996 Jan 27;347(8996):227-30.PMID: 8551882 [PubMed - indexed for MEDLINE]Related articles

    16.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.

    Xiang AH, Peters RK, Kjos SL, Ochoa C, Marroquin A, Goico J, Tan S, Wang C, Azen SP, Liu CR, Liu CH, Hodis HN, Buchanan TA.

    J Clin Endocrinol Metab. 2005 Apr;90(4):1986-91. Epub 2004 Dec 28.PMID: 15623809 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.

    Walter H, Lübben G.

    Drugs. 2005;65(1):1-13. Review.PMID: 15610048 [PubMed - indexed for MEDLINE]Related articles

    19.

    A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

    de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M.

    J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):313-43. Epub 2006 Mar 22.PMID: 16552630 [PubMed - indexed for MEDLINE]Related articles

    20.

    beta-cell failure in diabetes and preservation by clinical treatment.

    Wajchenberg BL.

    Endocr Rev. 2007 Apr;28(2):187-218. Epub 2007 Mar 12. Review.PMID: 17353295 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity